Who
Ghiath M. Sukhtian
Director and 10% owner
Company insider
Files Form 4 as: Director and 10% owner, Outlook Therapeutics.
In numbers
- Trades disclosed
- 46
- Buys
- 3
- Sells
- 0
- Bought
- $30.0M
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 31 Oct 2017
- Last trade
- 12 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 14 Aug 2026 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $2.5M2,525,252 at $0.99 | filing |
| 12 Aug 2026filed 14 Aug 2026 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —2,525,252 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —2,525,252 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $2.5M2,525,252 at $0.99 | filing |
| 28 May 2026filed 1 Jun 2026 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $5.0M8,539,709 at $0.5855 | filing |
| 28 May 2026filed 1 Jun 2026 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code H | —3,458,571 | filing |
| 28 May 2026filed 1 Jun 2026 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —3,458,571 | filing |
| 28 May 2026filed 1 Jun 2026 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code H | —3,458,571 | filing |
| 28 May 2026filed 1 Jun 2026 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —3,458,571 | filing |
| 28 May 2026filed 1 Jun 2026 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code H | —8,571,428 | filing |
| 28 May 2026filed 1 Jun 2026 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —8,571,428 | filing |
| 27 May 2025filed 28 May 2025 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,571,428 | filing |
| 27 May 2025filed 28 May 2025 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Code A | $6.0M4,285,714 at $1.40 | filing |
| 17 Jan 2025filed 12 Mar 2025 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Code M | $8.7M3,458,571 at $2.51 | filing |
| 18 Mar 2024filed 20 Mar 2024 | OTLK Outlook Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,458,571 | filing |
| 18 Mar 2024filed 20 Mar 2024 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,305,714 | filing |
| 28 Dec 2022filed 29 Dec 2022 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Code A | $12.5M14,230,418 at $0.88 | filing |
| 21 Apr 2022filed 7 Jul 2022 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Code J | —27,982,529 | filing |
| 29 Nov 2021filed 1 Dec 2021 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Bought | $20.0M16,000,000 at $1.25 | filing |
| 10 Feb 2021filed 11 Feb 2021 | OTLK Outlook TherapeuticsBiotechnology | SEC FORM 4 Code A | $1.0M1,013,627 at $1.00 | filing |
News
Reviewing Aprea Therapeutics (NASDAQ:APRE) & Oncobiologics (NASDAQ:OTLK)OTLK · themarketsdaily.com · 20 Oct 2026
0 headlines in the last 90 days name Ghiath M. Sukhtian; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.